Sélectionner une page

Parkinson et troubles du mouvement

Pour plus d’informations sur les essais cliniques sur la Parkinson et troubles du mouvement, veuillez contacter Salma Khalil.

 

Études actuelles en recrutement

 

Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

From clinicaltrials.gov:
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson’s disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson’s disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

More information

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

From clinicaltrials.gov:
The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

More information

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD)

From clinicaltrials.gov:
Part 1:
To determine the safety and tolerability of GZ/SAR402671 administered orally, as compared to placebo in patients with early-stage Parkinson’s disease (PD) carrying a GBA mutation or other pre-specified variants.
Part 2:
To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in patients with early-stage Parkinson’s disease carrying a GBA mutation or other pre-specified variants.
Secondary Objectives:

Part 1:
To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR4027671 in plasma when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.
To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.
Part 2:
To demonstrate overall safety and tolerability of GZ/SAR4027671 administered orally in early-stage Parkinson’s disease patients carrying a GBA mutation as compared to placebo.
To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage Parkinson’s disease patients carrying a GBA mutation.

The total study duration per subject in Part 2 will be approximately 168 weeks that will consist of 6.5 weeks of screening period, 52 weeks of treatment period, 104 weeks of follow-up period, and 6 weeks of post-treatment observation period. Part 1 maximal duration will be up to 48 weeks outside Japan, and up to 64 weeks in Japan.

More information